Evidence map›Paper›PMID 29959413›Full record

Trial reportLeukemia2019

Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.

Elias K Mai, Thomas Hielscher, Uta Bertsch, Jana Schlenzka, Hans J Salwender, Markus Munder, Christian Gerecke, Ulrich Dührsen, Peter Brossart, Kai Neben and 13 more

Abstract readClinical Trial, Phase IIIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Leukemia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 13 institutions in 1 country.

Elias K MaiDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany. elias.mai@med.uni-heidelberg.de.ORCID http://orcid.org/0000-0002-6226-1252
Thomas HielscherDivision of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Uta BertschDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
Jana SchlenzkaDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
Hans J SalwenderDepartment of Hematology and Oncology, Asklepios Hospital Hamburg Altona, Hamburg, Germany.
Markus MunderDepartment of Internal Medicine III, University Medical Center Mainz, Mainz, Germany.
Christian GereckeDepartment of Hematology and Oncology, Helios Hospital Berlin Buch, Berlin, Germany.
Ulrich DührsenDepartment of Hematology, University Clinic Essen, Essen, Germany.
Peter BrossartUniversity Hospital Bonn, Bonn, Germany.
Kai NebenDepartment of Hematology and Oncology, Klinikum Baden Baden, Baden Baden, Germany.
Jens HillengassDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
Marc S RaabDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
Maximilian MerzDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
Marc-Andrea BaertschDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
Anna JauchInstitute of Human Genetics, University of Heidelberg, Heidelberg, Germany.
Dirk HoseDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
Hans MartinDepartment of Medicine, Hematology/Oncology, Goethe-University of Frankfurt, Frankfurt, Germany.
Hans-Walter LindemannDepartment of Hematology and Oncology, Katholisches Krankenhaus Hagen, Hagen, Germany.
Igor W BlauMedical Clinic, Charité University Medicine Berlin, Berlin, Germany.
Christof ScheidDepartment of Internal Medicine I, University Hospital Köln, Köln, Germany.
Katja C WeiselDepartment of Hematology, Oncology and Immunology, University Hospital Tübingen, Tübingen, Germany.
Hartmut GoldschmidtDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
German-speaking Myeloma Multicenter Group (GMMG)
Heidelberg University · DEAsklepios Klinik Altona · DECharité - Universitätsmedizin Berlin · DEEssen University Hospital · DEGerman Cancer Research Center · DEGoethe University Frankfurt · DEHelios Hospital Berlin-Buch · DEJohannes Gutenberg University Mainz · DEKatholisches Krankenhaus St. Johann Nepomuk · DEKlinikum Mittelbaden · DEUniversity Children's Hospital Tübingen · DEUniversity Hospital Bonn · DEUniversity Hospital Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsBortezomibDexamethasoneFemaleFollow-Up StudiesHumansMaleMultiple MyelomaPrognosisRemission InductionRetrospective StudiesSurvival RateBortezomibDexamethasone

Identifiers

PMID29959413
OpenAlexW2809925189

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.